Literature DB >> 17001317

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

S-F Chin1, Y Wang, N P Thorne, A E Teschendorff, S E Pinder, M Vias, A Naderi, I Roberts, N L Barbosa-Morais, M J Garcia, N G Iyer, T Kranjac, J F R Robertson, S Aparicio, S Tavaré, I Ellis, J D Brenton, C Caldas.   

Abstract

We analysed 148 primary breast cancers using BAC-arrays containing 287 clones representing cancer-related gene/loci to obtain genomic molecular portraits. Gains were detected in 136 tumors (91.9%) and losses in 123 tumors (83.1%). Eight tumors (5.4%) did not have any genomic aberrations in the 281 clones analysed. Common (more than 15% of the samples) gains were observed at 8q11-qtel, 1q21-qtel, 17q11-q12 and 11q13, whereas common losses were observed at 16q12-qtel, 11ptel-p15.5, 1p36-ptel, 17p11.2-p12 and 8ptel-p22. Patients with tumors registering either less than 5% (median value) or less than 11% (third quartile) total copy number changes had a better overall survival (log-rank test: P=0.0417 and P=0.0375, respectively). Unsupervised hierarchical clustering based on copy number changes identified four clusters. Women with tumors from the cluster with amplification of three regions containing known breast oncogenes (11q13, 17q12 and 20q13) had a worse prognosis. The good prognosis group (Nottingham Prognostic Index (NPI) <or=3.4) tumors had frequent loss of 16q24-qtel. Genes significantly associated with estrogen receptor (ER), Grade and NPI were used to build k-nearest neighbor (KNN) classifiers that predicted ER, Grade and NPI status in the test set with an average misclassification rate of 24.7, 25.7 and 35.7%, respectively. These data raise the prospect of generating a molecular taxonomy of breast cancer based on copy number profiling using tumor DNA, which may be more generally applicable than expression microarray analysis.

Entities:  

Mesh:

Year:  2006        PMID: 17001317     DOI: 10.1038/sj.onc.1209985

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  mTOR generates an auto-amplification loop by triggering the βTrCP- and CK1α-dependent degradation of DEPTOR.

Authors:  Shanshan Duan; Jeffrey R Skaar; Shafi Kuchay; Alfredo Toschi; Naama Kanarek; Yinon Ben-Neriah; Michele Pagano
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

3.  Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.

Authors:  Dokyoon Kim; Ruowang Li; Scott M Dudek; Marylyn D Ritchie
Journal:  J Biomed Inform       Date:  2015-06-03       Impact factor: 6.317

Review 4.  Principles and methods of integrative genomic analyses in cancer.

Authors:  Vessela N Kristensen; Ole Christian Lingjærde; Hege G Russnes; Hans Kristian M Vollan; Arnoldo Frigessi; Anne-Lise Børresen-Dale
Journal:  Nat Rev Cancer       Date:  2014-05       Impact factor: 60.716

5.  Identification of 5 novel genes methylated in breast and other epithelial cancers.

Authors:  Victoria K Hill; Luke B Hesson; Temuujin Dansranjavin; Ashraf Dallol; Ivan Bieche; Sophie Vacher; Stella Tommasi; Timothy Dobbins; Dean Gentle; David Euhus; Cheryl Lewis; Reinhard Dammann; Robyn L Ward; John Minna; Eammon R Maher; Gerd P Pfeifer; Farida Latif
Journal:  Mol Cancer       Date:  2010-03-05       Impact factor: 27.401

6.  Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.

Authors:  Andrzej B Popławski; Michał Jankowski; Stephen W Erickson; Teresita Díaz de Ståhl; E Christopher Partridge; Chiquito Crasto; Jingyu Guo; John Gibson; Uwe Menzel; Carl Eg Bruder; Aneta Kaczmarczyk; Magdalena Benetkiewicz; Robin Andersson; Johanna Sandgren; Barbara Zegarska; Dariusz Bała; Ewa Srutek; David B Allison; Arkadiusz Piotrowski; Wojciech Zegarski; Jan P Dumanski
Journal:  Eur J Hum Genet       Date:  2010-01-06       Impact factor: 4.246

7.  Classification of arrayCGH data using fused SVM.

Authors:  Franck Rapaport; Emmanuel Barillot; Jean-Philippe Vert
Journal:  Bioinformatics       Date:  2008-07-01       Impact factor: 6.937

8.  An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.

Authors:  Raj Chari; Bradley P Coe; Emily A Vucic; William W Lockwood; Wan L Lam
Journal:  BMC Syst Biol       Date:  2010-05-17

9.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Authors:  Julie A Vendrell; Katherine E Robertson; Patrice Ravel; Susan E Bray; Agathe Bajard; Colin A Purdie; Catherine Nguyen; Sirwan M Hadad; Ivan Bieche; Sylvie Chabaud; Thomas Bachelot; Alastair M Thompson; Pascale A Cohen
Journal:  Breast Cancer Res       Date:  2008-10-17       Impact factor: 6.466

10.  Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down.

Authors:  José L Costa; Paul P Eijk; Mark A van de Wiel; Derk ten Berge; Fernando Schmitt; Carmen J Narvaez; JoEllen Welsh; Bauke Ylstra
Journal:  BMC Genomics       Date:  2009-10-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.